Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -26% Improvement Relative Risk Case 28% c19early.org/mf Oh et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 11,892 patients in the USA Fewer cases with metformin (p<0.000001) Oh et al., Acta Diabetologica, doi:10.1007/s00592-020-01666-7 Favors metformin Favors control
Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study
Oh et al., Acta Diabetologica, doi:10.1007/s00592-020-01666-7
Oh et al., Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database.., Acta Diabetologica, doi:10.1007/s00592-020-01666-7
Feb 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 27,493 type II diabetes patients in the USA, 7,204 on metformin, showing significantly lower COVID-19 cases, but no significant difference in mortality.
risk of death, 26.0% higher, OR 1.26, p = 0.30, treatment 5,946, control 5,946, adjusted per study, multivariable, RR approximated with OR.
risk of case, 28.0% lower, RR 0.72, p < 0.001, treatment 390 of 5,946 (6.6%), control 541 of 5,946 (9.1%), NNT 39, adjusted per study, odds ratio converted to relative risk, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Oh et al., 13 Feb 2021, retrospective, USA, peer-reviewed, 2 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: Acta Diabetologica (2021) 58:771–778 https://doi.org/10.1007/s00592-020-01666-7 ORIGINAL ARTICLE Metformin use and risk of COVID‑19 among patients with type II diabetes mellitus: an NHIS‑COVID‑19 database cohort study Tak Kyu Oh1 · In‑Ae Song1 Received: 7 September 2020 / Accepted: 26 December 2020 / Published online: 13 February 2021 © Springer-Verlag Italia S.r.l., part of Springer Nature 2021 Abstract Aims The relationship between metformin therapy and the risk of coronavirus disease (COVID-19) has not been reported among patients with type 2 diabetes mellitus (DM). We aimed to investigate whether metformin therapy was associated with the incidence of COVID-19 among type 2 DM patients in South Korea. Methods The National Health Insurance Service-COVID-19 cohort database, comprising COVID-19 patients from 1 January 2020 to 4 June 2020, was used for this study. Among them, adult patients with type 2 DM were included in this study. Metformin users were defined as those who had been prescribed continuous oral metformin for over a period of ≥ 90 days, and the control group was defined as all other patients. Results Overall, 27,493 patients with type 2 DM (7204, metformin user group; 20,289, control group) were included. After propensity score matching, 11,892 patients (5946 patients in each group) were included in the final analysis. In the logistic regression analysis, the odds of metformin users developing COVID-19 was 30% lower than that of the control group [odds ratio (OR): 0.70, 95% confidence interval (CI): 0.61–0.80; P < 0.001]. However, in the multivariate model, metformin use was not associated with hospital mortality when compared with that of the control group (OR: 1.26, 95% CI: 0.81–1.95; P = 0.301). Conclusions Metformin therapy might have potential benefits for the prevention of COVID-19 among patients with type 2 DM in South Korea. However, it did not affect the hospital mortality of type 2 DM patients diagnosed with COVID-19. Keywords Antidiabetic drug · Cohort study · Metformin · Type 2 diabetes
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit